


Joseph Anderson, Ph.D., M.A.S.

Clinical Interests	Dr. Anderson's research interests are in HIV stem cell gene therapy, and focus on translating key research findings into clinical applications for the treatment of infected individuals.
Research/Academic Interests	Dr. Anderson's research interests include Hematopoietic stem cell gene therapy for the treatment of various diseases including HIV, lysosomal storage diseases, and neurological diseases. His research efforts focus on developing therapies for these diseases and moving them toward human clinical trials.
Title	Associate Professor/Associate Professor In Residence
Specialty	Infectious Diseases, Internal Medicine
Department	Internal Medicine
Division	Infectious Diseases
Center/Program Affiliation	Northern California Center for AIDS Research Institute for Regenerative Cures Stem Cell Research Program
Additional Phone	Clinic Phone: 916-703-9300 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.A.S., University of California Davis, Sacramento CA 2018 Ph.D., Colorado State University, Fort Collins, Colorado, 2005 B.S., University of Wisconsin, La Crosse WI 2000
Professional Memberships	American Society of Gene and Cellular Therapy
Honors and Awards	Acceptance into the UC Davis Mentored Clinical Research Training Program., 2013 UC Davis Academic Federation Travel Award 2011, 2012, 2013 UC Davis Academic Federation Innovative Development Award, 2012 First place award for poster at "Medical Student Research and Poster Forum" at UC-Davis Medical Center, Symposium, 2009 American Society of Hematology Travel Award for abstract poster presentation at ASH conference, 2008
Select Recent Publications	Yuan O, Lin C, Wagner J, Archard JA, Deng P, Halmaj J, Bauer G, Fink KD, Fury B, Perotti NH, Walker JE, Pollock K, Apperson M, Butters J, Belafsky P, Farwell DG, Kuhn M, Nolte J, Anderson JD, Anderson JS. Exosomes Derived from Human Primed Mesenchymal Stem Cells Induce Mitosis



Joseph Anderson, Ph.D., M.A.S.

and Potentiate Growth Factor Secretion. *Stem Cell Dev.* 2019;28(6):398-409.

Fink KD, Deng P, Gutierrez J, Anderson JS, Torrest A, Komarla A, Kalomoiris S, Cary W, Anderson JD, Gruenloh W, Duffy A, Tempkin T, Annett G, Wheelock V, Segal DJ, Nolte JA. Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts. *Cell Transplant.* 2016;4(25):677-86.

Konadu KA, Anderson JS, Huang M-B, Ali SA, Powell MD, Villinger F, and Bond VC. Hallmarks of HIV-1 pathogenesis are modulated by Nef's Secretion Modification Region. *Journal of AIDS and Clinical Research.* 2015;6(7):476.


Anderson JS and Bauer G. Stem Cell Transplantation in the context of HIV: How Can We Cure HIV Infection? *Expert Reviews in Clinical Immunology.* 2014;10(1):107-116.

Gericota B, Anderson JS, Mitchell G, Borjesson DL, Sturges BK, Nolte JA, and Sieber-Blum M. Canine epidermal neural crest stem cells: characterization and potential as therapy candidate for a large animal model of spinal cord injury. *Stem Cells Translational Medicine.* 2014;(3):334-345.

Yang Y, Zhang S, Fong R, Barraza A, Nolte JA, Torbett BE, Abedi M, Bauer G, and Anderson JS. Safety and efficacy of a tCD25 Preselective Combination Anti-HIV Lentiviral Vector in Human Hematopoietic Stem and Progenitor Cells. *Stem Cells.* 2014;33(3): 870-879.

Kalomoiris S, Lawson J, Chen RX, Bauer G, Nolte JA, and Anderson JS. CD25 preselective anti-HIV vectors for improved HIV gene therapy. *Human Gene Therapy Methods,* 2012;23: 366-375.

Anderson JS and Bauer G. Fighting HIV with stem cell therapy: one step closer to human trials? *Expert Review of Anti-Infective Therapy,* 2012;10: 1071-1073.



Joseph Anderson, Ph.D., M.A.S.

Walker JE, Chen RX, McGee J, Nacey C, Pollard RB, Abedi M, Bauer G, Nolta JA, and Anderson JS. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector. *Journal of Virology*, 2012;86: 5719-5729.

Anderson JS. Using TRIM5alpha as an HIV therapeutic: the alpha gene? *Expert Opinion on Biological Therapy*, 2013;13: 1029-1038.

© 2021 UC Regents